Table 1
Baseline characteristics of patient cohort
| Mean (SD) | n (%) | |
| Age (years) | 62 (10.7) | |
| Male | 93 (70) | |
| Diabetes | 12 (9) | |
| Hypertension | 29 (22) | |
| Smoker | 69 (52) | |
| Cholesterol (mmol/l) | 6.0 (1.25) | |
| Creatine (mmol/l) | 106 (19.0) | |
| Anterior myocardial infarction | 56 (42) | |
| Tissue type plasminogen activator given | 8 (6) | |
| Angiotensin converting enzyme | 61 (48) | |
| β blocker | 89 (70) | |
| Aspirin | 117 (91) | |
| Cholesterol lowering agent | 37 (29) | |
| Early ESVi (ml/m2) | 26 (9.7) | |
| Early EDVi (ml/m2) | 45 (12.9) | |
| Early ejection fraction (%) | 44 (9.7) | |
| Early WMI | 1.5 (0.38) | |
| Late ESVi (ml/m2) | 27 (10.8) | |
| Late EDVi (ml/m2) | 46 (14.1) | |
| Late ejection fraction (%) | 43 (9.2) | |
| Late WMI | 1.6 (0.38) |
-
EDVi, end diastolic volume index; ESVi, end systolic volume index; WMI, wall motion index
